Mariana Letícia de Bastos Maximiano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mariana Letícia de Bastos Maximiano has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Lucas Machado Magalhães
Faculty of Medicine, Institute of Medical Education, Angra dos Reis, Brazil
5 shared publications - Anderson Matheus Pereira da Silva
Department of Physiology and Pharmacology, Federal University of Pernambuco, Recife, Brazil
4 shared publications - Ocílio Ribeiro Gonçalves
Federal University of Piaui
4 shared publications - Ahmet Günkan
Department of Radiology and Imaging Sciences, Division of Interventional Radiology, University of Arizona Medical Center, Tucson, USA
3 shared publications - Filipe Virgilio Ribeiro
Faculty of Medicine, Barão de Mauá University Center, Ribeirão Preto, SP, Brazil
3 shared publications - João Victor Pereira Gonzalez
Department of Medicine, Bahiana School of Medicine and Public Health, Salvador, Brazil
3 shared publications
Latest Publications
- 6 November 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Reply to “Caution Needed Regarding Conclusions of Meta-Analysis of Coenzyme Q10 as Treatment for Depressive Symptoms”
Was not provided for this article.
- 6 November 2026
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
Reply to “Caution Needed Regarding Conclusions of Meta-Analysis of Coenzyme Q10 as Treatment for Depressive Symptoms”
Was not provided for this article.
- 20 August 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2117-2128
Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis
Objectives/Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta‐analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP‐1 RAs in patients with IIH, focusing on clinical outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP‐1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances. Results: Eight studies comprising 13,243 patients met inclusion criteria. GLP‐1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281–0.659; I ‐squared statistic [ I 2 ] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382–0.576; I 2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557–0.853; I 2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691–0.916; I 2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304–0.547; I 2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236–0.796; I 2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574–0.843; I 2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715–0.908; I 2 = 52.0%) compared to control group. Conclusion: GLP‐1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low‐certainty, hypothesis‐generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.
- 20 August 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2117-2128
Glucagon‐like peptide‐1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta‐analysis
Objectives/Background: Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially developed for type 2 diabetes and obesity, have emerged as promising candidates for idiopathic intracranial hypertension (IIH) due to their metabolic and neurophysiological effects. This systematic review and meta‐analysis aims to summarize, synthesize, and quantitatively pool the available evidence on the use of GLP‐1 RAs in patients with IIH, focusing on clinical outcomes. Methods: PubMed, Embase, Web of Science, and the Cochrane Library were searched through December 2025 for randomized trials and cohort studies assessing GLP‐1 RAs in patients with IIH. Risk of bias was assessed by Risk of Bias in Nonrandomized Studies of Interventions and Cochrane Risk of Bias 2.0. Primary outcomes included papilledema, headache burden, refractory IIH, and visual disturbances. Results: Eight studies comprising 13,243 patients met inclusion criteria. GLP‐1 RAs significantly reduced papilledema risk at 3 months (risk ratio [RR], 0.430; 95% confidence interval [CI], 0.281–0.659; I ‐squared statistic [ I 2 ] = 62.5%) and maintained the benefit through 24 months (RR, 0.469; 95% CI, 0.382–0.576; I 2 = 18.0%). Headache frequency was also consistently lower at 3 months (RR, 0.690; 95% CI, 0.557–0.853; I 2 = 71.0%) and at 24 months (RR, 0.796; 95% CI, 0.691–0.916; I 2 = 68.9%), with similar improvements in visual disturbances at 3 months (RR, 0.408; 95% CI, 0.304–0.547; I 2 = 36.0%) and 24 months (RR, 0.433; 95% CI, 0.236–0.796; I 2 = 79.0%), and refractory IIH at 3 months (RR, 0.696; 95% CI, 0.574–0.843; I 2 = 60.0%) and 24 months (RR, 0.808; 95% CI, 0.715–0.908; I 2 = 52.0%) compared to control group. Conclusion: GLP‐1 RAs appear associated with improvements in clinical outcomes in IIH, including reductions in papilledema, headache, and visual symptoms. The current evidence base is dominated by observational studies with moderate to serious risk of confounding, resulting in low‐certainty, hypothesis‐generating evidence. These findings should be interpreted cautiously and primarily serve to inform the design of future well powered randomized controlled trials.
- 11 April 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Reperfusion therapy in pregnant and postpartum women after ischemic stroke: a systematic review and single-arm meta-analysis
Ischemic stroke during pregnancy and postpartum represents a rare but severe clinical event. Although reperfusion therapies like intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are standard in the general population, their use in pregnant and postpartum patients remains controversial due to limited data. Therefore, this study aims to evaluate the safety and efficacy of reperfusion therapy in pregnant and postpartum women with acute ischemic stroke. Systematic review and single-arm meta-analysis of studies reporting outcomes in pregnant or postpartum women undergoing IVT or MT. Outcomes included maternal and fetal events, intracerebral hemorrhage (ICH), symptomatic ICH (sICH), functional recovery (mRS 0-2), and mortality. Six studies comprising 275 patients were included. The pooled proportion of good maternal outcomes at discharge was 50% (95% CI: 44%-56%), and 85% (95% CI: 53%-100%) achieved functional recovery at 3 months. In-hospital mortality was 0% (95% CI: 0%-1%). Hemorrhagic complications included 10% ICH (95% CI: 1%-20%) and 3% sICH (95% CI: 0%-9%). Good fetal outcomes were observed in 78% (95% CI: 50%-100%) of cases. Although limited, the results suggest that reperfusion therapy in pregnancy-related ischemic stroke is safe and potentially effective, with favorable maternal and fetal outcomes and low mortality rates. These findings support the use of reperfusion therapies associated with individualized decision-making-in line with European Stroke Organisation guidelines -, emphasizing that pregnancy and post-partum period should not be a contraindication to IVT or MT.
- 11 April 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-13
Reperfusion therapy in pregnant and postpartum women after ischemic stroke: a systematic review and single-arm meta-analysis
Ischemic stroke during pregnancy and postpartum represents a rare but severe clinical event. Although reperfusion therapies like intravenous thrombolysis (IVT) and mechanical thrombectomy (MT) are standard in the general population, their use in pregnant and postpartum patients remains controversial due to limited data. Therefore, this study aims to evaluate the safety and efficacy of reperfusion therapy in pregnant and postpartum women with acute ischemic stroke. Systematic review and single-arm meta-analysis of studies reporting outcomes in pregnant or postpartum women undergoing IVT or MT. Outcomes included maternal and fetal events, intracerebral hemorrhage (ICH), symptomatic ICH (sICH), functional recovery (mRS 0-2), and mortality. Six studies comprising 275 patients were included. The pooled proportion of good maternal outcomes at discharge was 50% (95% CI: 44%-56%), and 85% (95% CI: 53%-100%) achieved functional recovery at 3 months. In-hospital mortality was 0% (95% CI: 0%-1%). Hemorrhagic complications included 10% ICH (95% CI: 1%-20%) and 3% sICH (95% CI: 0%-9%). Good fetal outcomes were observed in 78% (95% CI: 50%-100%) of cases. Although limited, the results suggest that reperfusion therapy in pregnancy-related ischemic stroke is safe and potentially effective, with favorable maternal and fetal outcomes and low mortality rates. These findings support the use of reperfusion therapies associated with individualized decision-making-in line with European Stroke Organisation guidelines -, emphasizing that pregnancy and post-partum period should not be a contraindication to IVT or MT.
- 22 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-12
Efficacy and safety of modafinil in post-stroke fatigue: a systematic review and meta-analysis
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.
- 22 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-12
Efficacy and safety of modafinil in post-stroke fatigue: a systematic review and meta-analysis
Post-stroke fatigue (PSF) is a common and disabling condition that limits rehabilitation and quality of life, yet no pharmacological treatment is well established. Modafinil, a wakefulness-promoting agent, has been proposed as a potential therapy. This systematic review and meta-analysis evaluated its efficacy and safety in PSF. Four studies (two RCTs, two observational) comprising 1001 met inclusion criteria. Modafinil did not significantly improve overall fatigue severity on the MFI or FSS. A domain-specific benefit was observed for mental fatigue (MD -2.51; p = 0.0005), with no significant effects on physical, general, or activity-related fatigue. No improvements were found in quality of life (SSQoL) or cognition (MoCA). Modafinil was generally well tolerated with few mild adverse events. Current evidence does not support modafinil as a routine treatment for PSF. Its effect on mental fatigue is of very low certainty, limiting the strength of this finding. Clinicians should interpret these findings cautiously, and use modafinil only on a case-by-case basis. Larger, high-quality trials with standardized fatigue measures are needed to identify responders and clarify its clinical role.
- 14 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Dual antiplatelet therapy pretreatment in patients undergoing intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of 296,854 patients
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.
- 14 February 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Dual antiplatelet therapy pretreatment in patients undergoing intravenous thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of 296,854 patients
Wea im to evaluate the impact of Dual Antiplatelet Therapy (DAPT) pretreatment on outcomes in patients with Acute Ischemic Stroke (AIS) undergoing intravenous thrombolysis (IVT). A systematic search was conducted from inception to January 2025. Eligible studies included randomized and observational cohorts comparing AIS patients with and without DAPT pretreatment who underwent IVT. Primary outcome was favorable functional outcome at 90 days (mRS 0-1). Secondary outcomes included mRS 0-2, mRS 3-6, in-hospital and 90-day mortality, and symptomatic intracranial hemorrhage (sICH) defined by SITS-MOST, ECASS II, and NINDS criteria. Risk of bias was assessed using the ROBINS-I tool, and meta-analyses were performed with random-effects models. Eight studies including 296,854 patients (61,925 with DAPT and 234,929 without DAPT) were analyzed. DAPT pretreatment was not associated with favorable functional outcome (mRS 0-1; OR: 1.03; 95% CI: 0.92-1.16; p = 0.57; I2 = 0%), in-hospital mortality (OR: 1.00; 95% CI: 1.00-1.00; I2 = 0%), or 90-day mortality (OR: 1.49; 95% CI: 0.99-2.25; p = 0.06; I2 = 52%). No significant increase in sICH was observed using SITS-MOST (I2 = 64%) or ECASS II (I2 = 63%), whereas sICH defined by NINDS was increased (OR: 1.31; 95% CI: 1.19-1.44; p < 0.01; I2 = 48%), corresponding to a 1% absolute risk increase (RD: 0.01; I2 = 0%). Prestroke DAPT was not associated with favorable functional outcome or reduced mortality after IVT and was associated with a higher risk of sICH when defined by NINDS criteria, with a 1% absolute risk increase.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Efficacy and safety of Pipeline Embolization Device versus Tubridge flow diverter for unruptured intracranial aneurysms: a systematic review and meta-analysis
To compare the outcomes of flow diversion treatment with Pipeline Embolization Device (PED) and Tubridge Flow Diverter (TFD) in unruptured intracranial aneurysms. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. The primary outcome was complete aneurysm occlusion. Secondary outcomes included favorable functional outcomes (modified Rankin Scale 0-2), perioperative ischemic and hemorrhagic complications, and in-stent stenosis. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using the Mantel-Haenszel method under a random-effects model. Heterogeneity was assessed using the I2 statistic. Statistical analyses were performed using R software (version 4.4.0). Four studies including 913 patients were analyzed; 462 underwent treatment with TFD and 451 with PED. Complete aneurysm occlusion was achieved in 75.96% of TFD cases and 81.64% of PED cases (RR: 0.93; 95% CI: 0.87-1.00; I2 = 0%). Favorable functional outcomes occurred in 97.07% (TFD) and 96.84% (PED) (RR: 1.00; 95% CI: 0.98-1.02; I2 = 0%). Ischemic complications were slightly higher in TFD (4.11%) than in PED (2.44%) (RR: 1.67; 95% CI: 0.39-7.10; I2 = 53.7%). Hemorrhagic complications were low in both groups (0.26% vs. 0.54%; RR: 0.55; 95% CI: 0.07-4.39; I2 = 0%). In-stent stenosis occurred in 15.06% (TFD) and 16.08% (PED) (RR: 0.94; 95% CI: 0.66-1.33; I2 = 0%). PED and TFD demonstrate comparable efficacy and safety profiles for the treatment of unruptured intracranial aneurysms. Both devices are effective options for endovascular therapy.
- 26 January 2026
- Published by Taylor & Francis in Neurological Research
- p. 1-14
Efficacy and safety of Pipeline Embolization Device versus Tubridge flow diverter for unruptured intracranial aneurysms: a systematic review and meta-analysis
To compare the outcomes of flow diversion treatment with Pipeline Embolization Device (PED) and Tubridge Flow Diverter (TFD) in unruptured intracranial aneurysms. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. The primary outcome was complete aneurysm occlusion. Secondary outcomes included favorable functional outcomes (modified Rankin Scale 0-2), perioperative ischemic and hemorrhagic complications, and in-stent stenosis. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using the Mantel-Haenszel method under a random-effects model. Heterogeneity was assessed using the I2 statistic. Statistical analyses were performed using R software (version 4.4.0). Four studies including 913 patients were analyzed; 462 underwent treatment with TFD and 451 with PED. Complete aneurysm occlusion was achieved in 75.96% of TFD cases and 81.64% of PED cases (RR: 0.93; 95% CI: 0.87-1.00; I2 = 0%). Favorable functional outcomes occurred in 97.07% (TFD) and 96.84% (PED) (RR: 1.00; 95% CI: 0.98-1.02; I2 = 0%). Ischemic complications were slightly higher in TFD (4.11%) than in PED (2.44%) (RR: 1.67; 95% CI: 0.39-7.10; I2 = 53.7%). Hemorrhagic complications were low in both groups (0.26% vs. 0.54%; RR: 0.55; 95% CI: 0.07-4.39; I2 = 0%). In-stent stenosis occurred in 15.06% (TFD) and 16.08% (PED) (RR: 0.94; 95% CI: 0.66-1.33; I2 = 0%). PED and TFD demonstrate comparable efficacy and safety profiles for the treatment of unruptured intracranial aneurysms. Both devices are effective options for endovascular therapy.
- 26 November 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (1) , 93-100
Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue
Background: Coenzyme Q10 (CoQ10) is a mitochondrial cofactor with antioxidant and anti-inflammatory properties that may counteract mechanisms implicated in depression, such as oxidative stress and mitochondrial dysfunction. We evaluated the efficacy of CoQ10 supplementation on depressive symptoms and fatigue in patients with depression, whether as a primary disorder or in the context of underlying medical illness. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Randomized controlled trials comparing CoQ10 with placebo or standard treatment in patients diagnosed with depression were eligible, independent of concomitant medical conditions. Outcomes included changes in depressive symptoms and fatigue. Data were pooled using random-effects models, with standardized mean differences (SMD) and 95% CIs. Heterogeneity was assessed with the I 2 statistic, and sensitivity analyses were performed using a leave-one-out approach. Results: Five RCTs with 474 participants were included. Three trials enrolled patients with depression associated with significant medical conditions—multiple sclerosis, breast cancer, and polycystic ovary syndrome—while 2 included patients with primary depressive disorders (major depression and bipolar disorder). CoQ10 supplementation significantly reduced depressive symptoms compared with control (SMD: −0.68; 95% CI: −1.02 to −0.33; P I 2 =58%), with consistent results across rating scales. Sensitivity analysis indicated that heterogeneity was largely driven by a single study. No significant benefit was observed for fatigue (SMD: −0.33; 95% CI: −1.38 to 0.72; P =0.54; I 2 =89%), based on only 2 trials. Conclusions: CoQ10 supplementation may confer moderate improvement in depressive symptoms across diverse populations. However, the evidence for fatigue remains inconclusive.
- 26 November 2025
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 46 (1) , 93-100
Effects of Coenzyme Q10 Supplementation on Depressive Symptoms and Fatigue
Background: Coenzyme Q10 (CoQ10) is a mitochondrial cofactor with antioxidant and anti-inflammatory properties that may counteract mechanisms implicated in depression, such as oxidative stress and mitochondrial dysfunction. We evaluated the efficacy of CoQ10 supplementation on depressive symptoms and fatigue in patients with depression, whether as a primary disorder or in the context of underlying medical illness. Methods: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Randomized controlled trials comparing CoQ10 with placebo or standard treatment in patients diagnosed with depression were eligible, independent of concomitant medical conditions. Outcomes included changes in depressive symptoms and fatigue. Data were pooled using random-effects models, with standardized mean differences (SMD) and 95% CIs. Heterogeneity was assessed with the I 2 statistic, and sensitivity analyses were performed using a leave-one-out approach. Results: Five RCTs with 474 participants were included. Three trials enrolled patients with depression associated with significant medical conditions—multiple sclerosis, breast cancer, and polycystic ovary syndrome—while 2 included patients with primary depressive disorders (major depression and bipolar disorder). CoQ10 supplementation significantly reduced depressive symptoms compared with control (SMD: −0.68; 95% CI: −1.02 to −0.33; P I 2 =58%), with consistent results across rating scales. Sensitivity analysis indicated that heterogeneity was largely driven by a single study. No significant benefit was observed for fatigue (SMD: −0.33; 95% CI: −1.38 to 0.72; P =0.54; I 2 =89%), based on only 2 trials. Conclusions: CoQ10 supplementation may confer moderate improvement in depressive symptoms across diverse populations. However, the evidence for fatigue remains inconclusive.
- 6 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (2) , 177-187
Decompressive craniectomy versus best medical treatment alone for spontaneous intracerebral hemorrhage: A systematic review and meta-analysis
Background: While managing spontaneous intracerebral hemorrhage (sICH) has advanced, achieving favorable outcomes remains challenging. Recent studies suggest that decompressive craniectomy (DC) may offer benefits over conservative treatment, consisting of the best medical treatment (BMT) in certain sICH cases. Aim: This study aims to compare DC to BMT alone for sICH regarding functional neurological outcomes, mortality, and length of hospitalization. Methods: Randomized and observational studies were identified comparing surgery (DC) to conservative management alone for patients with sICH. The outcomes analyzed were modified Rankin Scale (mRS), mortality at 30 days, 90 days, and overall mortality, and length of hospital stay. The odds ratio (OR) and mean difference (MD) were calculated for binary and continuous outcomes. Results: Our analysis included eight studies (n = 743), with 345 patients undergoing surgery and 398 undergoing conservative management. BMT alone was associated with a poor neurological function (mRS of 5–6) (OR = 0.44; 95% CI = 0.24–0.78; p-value = 0.005; I 2 = 39.8%), while the rate of good neurological function (mRS = 0–4) was superior in the surgical cohort (OR = 2.29; 95% CI = 1.28–4.10; p = 0.005; I 2 = 39.8%), despite the lack of statistical significance for mRS 0–2 (OR = 1.25; 95% CI = 0.47–3.33; p = 0.66; I 2 = 0%) and mRS 0–3 (OR = 1.43; 95% CI = 0.82–2.51; p = 0.21; I 2 = 0%). Conservative management was associated with higher mortality at 30 days (OR = 0.36; 95% CI = 0.19–0.66; p-value = 0.001; I 2 = 0%), at 90 days (OR = 0.35; 95% CI = 0.14–0.86; p = 0.022; I 2 = 68.7%), and at last follow-up (OR = 0.33; 95% CI = 0.21–0.52; p-value < 0.001; I 2 = 34.8%). Length of hospital stay was superior in the DC cohort, but without statistical significance (MD = 16.05; 95% CI = −3.24 to 35.34; p-value = 0.1; I 2 = 92.9%). Conclusions: In patients with sICH, decompressive craniectomy shows potential for reducing mortality and improving neurological function compared to BMT alone. Further randomized studies, with improved methods, are needed to increase the quality of evidence.
- 6 September 2025
- Published by SAGE Publications in International Journal of Stroke
- Vol. 21 (2) , 177-187
Decompressive craniectomy versus best medical treatment alone for spontaneous intracerebral hemorrhage: A systematic review and meta-analysis
Background: While managing spontaneous intracerebral hemorrhage (sICH) has advanced, achieving favorable outcomes remains challenging. Recent studies suggest that decompressive craniectomy (DC) may offer benefits over conservative treatment, consisting of the best medical treatment (BMT) in certain sICH cases. Aim: This study aims to compare DC to BMT alone for sICH regarding functional neurological outcomes, mortality, and length of hospitalization. Methods: Randomized and observational studies were identified comparing surgery (DC) to conservative management alone for patients with sICH. The outcomes analyzed were modified Rankin Scale (mRS), mortality at 30 days, 90 days, and overall mortality, and length of hospital stay. The odds ratio (OR) and mean difference (MD) were calculated for binary and continuous outcomes. Results: Our analysis included eight studies (n = 743), with 345 patients undergoing surgery and 398 undergoing conservative management. BMT alone was associated with a poor neurological function (mRS of 5–6) (OR = 0.44; 95% CI = 0.24–0.78; p-value = 0.005; I 2 = 39.8%), while the rate of good neurological function (mRS = 0–4) was superior in the surgical cohort (OR = 2.29; 95% CI = 1.28–4.10; p = 0.005; I 2 = 39.8%), despite the lack of statistical significance for mRS 0–2 (OR = 1.25; 95% CI = 0.47–3.33; p = 0.66; I 2 = 0%) and mRS 0–3 (OR = 1.43; 95% CI = 0.82–2.51; p = 0.21; I 2 = 0%). Conservative management was associated with higher mortality at 30 days (OR = 0.36; 95% CI = 0.19–0.66; p-value = 0.001; I 2 = 0%), at 90 days (OR = 0.35; 95% CI = 0.14–0.86; p = 0.022; I 2 = 68.7%), and at last follow-up (OR = 0.33; 95% CI = 0.21–0.52; p-value < 0.001; I 2 = 34.8%). Length of hospital stay was superior in the DC cohort, but without statistical significance (MD = 16.05; 95% CI = −3.24 to 35.34; p-value = 0.1; I 2 = 92.9%). Conclusions: In patients with sICH, decompressive craniectomy shows potential for reducing mortality and improving neurological function compared to BMT alone. Further randomized studies, with improved methods, are needed to increase the quality of evidence.
- Open Access
- 1 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (10) , 001-007
Prognostic biomarkers in ischemic stroke treated with mechanical thrombectomy: a systematic review
Mechanical thrombectomy (MT) is a key therapy for acute ischemic stroke (AIS), improving survival and functional outcomes. However, the variability in results highlights the need for predictive markers to refine patient selection. Biomarkers reflecting inflammation and metabolic stress are gaining recognition for their role in AIS and MT outcomes. To systematically review and synthesize the evidence on biomarkers associated with clinical outcomes in AIS patients undergoing MT. Specific aims include evaluating their relationship with functional recovery (mRS), mortality, infarct volume, hemorrhagic transformation, and complications such as malignant brain edema (MBE) and delayed cerebral ischemia (DCI). A systematic review of the literature was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to identify studies evaluating biomarkers in MT. The PubMed and Embase databases were searched using the following terms: (Marker OR biomarker*) AND (Mechanical Thrombectomy OR endovascular) AND Stroke. Of 2,834 articles identified, 86 met inclusion criteria. Several biomarkers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), adenosine deaminase (ADA), neuron-specific enolase (NSE), and matrix metalloproteinase-9 (MMP-9), were consistently associated with worse functional outcomes, increased mortality, and higher risk of complications including hemorrhagic transformation and MBE. Multiple biomarkers demonstrate prognostic value in AIS patients undergoing MT. These findings may support risk stratification and individualized care, though further prospective studies are needed to integrate these biomarkers into the clinical practice.
- 1 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (10) , 001-007
Open AccessPrognostic biomarkers in ischemic stroke treated with mechanical thrombectomy: a systematic review
Mechanical thrombectomy (MT) is a key therapy for acute ischemic stroke (AIS), improving survival and functional outcomes. However, the variability in results highlights the need for predictive markers to refine patient selection. Biomarkers reflecting inflammation and metabolic stress are gaining recognition for their role in AIS and MT outcomes. To systematically review and synthesize the evidence on biomarkers associated with clinical outcomes in AIS patients undergoing MT. Specific aims include evaluating their relationship with functional recovery (mRS), mortality, infarct volume, hemorrhagic transformation, and complications such as malignant brain edema (MBE) and delayed cerebral ischemia (DCI). A systematic review of the literature was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement to identify studies evaluating biomarkers in MT. The PubMed and Embase databases were searched using the following terms: (Marker OR biomarker*) AND (Mechanical Thrombectomy OR endovascular) AND Stroke. Of 2,834 articles identified, 86 met inclusion criteria. Several biomarkers, such as C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), adenosine deaminase (ADA), neuron-specific enolase (NSE), and matrix metalloproteinase-9 (MMP-9), were consistently associated with worse functional outcomes, increased mortality, and higher risk of complications including hemorrhagic transformation and MBE. Multiple biomarkers demonstrate prognostic value in AIS patients undergoing MT. These findings may support risk stratification and individualized care, though further prospective studies are needed to integrate these biomarkers into the clinical practice.